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2Introduction
Interferon beta-1b (IFNB-1b) administered subcuta-
neously (sc) every other day (eod) has been demon-
strated to be a beneficial treatment for patients with re-
lapsing-remitting multiple sclerosis (RRMS) [9, 16] and
secondary progressive MS [7, 14]. Recently, the
BEtaferon/BEtaseron in Newly Emerging MS For Initial
Treatment (BENEFIT) study showed that IFNB-1b sc
eod is also effective at slowing the development of re-
current active disease from a first clinical event (clini-
cally isolated syndrome; CIS) to the second event, sug-
gesting that this therapy should be considered as a
therapeutic option immediately after presentation of
the disease [11].
As a well-controlled, multi-centre study with the
highest number of CIS patients studied to assess the ef-
fect of early IFNB therapy to date, the BENEFIT study
was well suited to address questions on risk modifica-
tion and treatment response in various subgroups of the
CIS population, which included patients with or without
steroid treatment for the first event.
We performed further analyses on the BENEFIT data
to determine (i) the impact of the key demographic,
clinical and MRI parameters on the ‘natural’ risk of MS
in placebo-treated patients and (ii) the IFNB-1b treat-
ment effect in subgroups of the study population.We fo-
cused on ‘time to clinically definite MS’ (CDMS) which
we considered to have the highest clinical relevance for
the evaluation of the disease evolution and treatment re-
sponse in a CIS population over a 2-year observation pe-
riod.
Patients and methods
■ Study design, patients, and procedures
The design and main outcomes of the BENEFIT trial have been re-
ported elsewhere [11].Briefly, the BENEFIT study was a double-blind,
placebo-controlled, randomised, parallel-group, multi-centre, phase
III study that evaluated the safety, tolerability and efficacy of IFNB-1b
250 μg (8 MIU) sc eod in CIS patients. Eligible patients were aged be-
tween 18 and 45 years; had presented with a first clinical event sug-
gestive of MS that lasted for at least 24 hours; had at least 2 clinically
silent lesions on a T2-weighted brain MRI scan with a minimum size
of 3 mm of which at least 1 was ovoid, periventricular or infratentor-
ial; and had a baseline Expanded Disability Status Scale (EDSS) score
between 0 and 5. Patients with signs and symptoms that could be ex-
plained by a disease other than MS, and patients with a previous de-
myelinating event,complete transverse myelitis or bilateral optic neu-
ritis or previous immunosuppressive therapy were excluded.
Patient eligibility was confirmed prior to randomisation by the
central reading centre at the VU Medical Center (Amsterdam, The
Netherlands) – documented clinical signs and symptoms were used
to classify the first demyelinating event, as either monofocal (signs
and symptoms could be explained by 1 CNS lesion) or multifocal
(signs and symptoms could only be explained by more than 1 CNS le-
sion). Considerable emphasis was given to a systematic classification
of the clinical presentation. In all patients, the local neurologist was
asked to document all neurological symptoms reported by the patient
at the time of the first event, as well as all clinical signs obtained at the
neurological examination. At the central reading centre, all patients
were subsequently classified as mono- or multifocal according to a
standardised scheme that took all information on patients’ signs and
symptoms into account,as previously described [21].Briefly,based on
the reported neurological symptoms, the location of the minimum
number of lesions that could explain all symptoms was determined.
Subsequently, using all information from the standardised neurolog-
ical examination (i.e. the signs), a decision was made regarding
whether or not these abnormalities could be explained by the lesions
already identified based on symptoms. If not, the presence of an ad-
ditional lesion (due to signs) was indicated. This classification was
performed by two neurologists who were unaware of the MRI results
and treatment allocation.
Patients were randomly assigned in a 5:3 ratio to IFNB-1b 250 μg
■ Abstract Background The BEN-
EFIT study examined interferon
beta (IFNB)-1b treatment in pa-
tients with clinically isolated syn-
drome (CIS) and ≥ 2 clinically
silent brain MRI lesions. Methods
Subgroups of 468 patients (IFNB-
1b: n = 292; placebo: n = 176) were
created for demographics, clinical,
laboratory, and MRI findings at on-
set. The ‘natural’ risk of clinically
definite MS (CDMS) over 2 years
was estimated by Kaplan Meier sta-
tistics in placebo-treated patients;
the IFNB-1b treatment effect was
analysed by Cox proportional haz-
ards regression. Results The risk of
CDMS was increased in placebo-
treated patients (overall 45 %) if
they were younger (< 30 years:
60 %), were cerebrospinal fluid
(CSF)-positive (49 %), or had re-
ceived steroid treatment (48 %).
MRI parameters implied a higher
risk in placebo-treated patients
with ≥ 9 T2-lesions (48 %) or ≥ 1
gadolinium (Gd)-enhancing le-
sions (52 %). The CDMS risk was
highest (75 %) in placebo-treated
patients with monofocal disease
onset displaying MRI disease activ-
ity (≥ 1 Gd-lesion) and dissemina-
tion (≥ 9 T2-lesions). Treatment ef-
fects were significant across almost
all subgroups including patients
with less disease dissemination/ac-
tivity at onset (monofocal: 55 %;
< 9 T2-lesions: 60 %; no Gd-lesions:
57 %) and patients without steroid
treatment for the CIS (62 %).
Monofocal patients had greater
treatment effects if they had ≥ 9 T2-
lesions (61 %), Gd-lesions (58 %),
or both (65 %). Conclusions This
study confirms the impact of age of
onset, CSF and MRI findings on
risk of conversion from CIS to
CDMS. IFNB-1b treatment effect
was robust across the study popu-
lation including patients without
MRI disease activity and less clini-
cal or MRI disease dissemination at
onset and patients not receiving
steroids for the CIS.
■ Key words multiple sclerosis ·
CIS · MRI
3or placebo sc eod for up to 24 months or until CDMS was diagnosed
using modified Poser criteria [17]. The study treatment was initiated
within 60 days after establishment of the first clinical event. Visits
were scheduled for collection of EDSS, MRI, and other efficacy data,
as well as for safety data, at months 3, 6, 9, 12, 18 and 24.All MRI scans
were performed with 0.1 mmol/kg gadolinium (Gd)-diethylenetri-
amine penta-acetic acid (DTPA). MRI scan assessment was per-
formed centrally at the VU Medical Centre, Amsterdam, The Nether-
lands by readers who were blinded to clinical data and treatment
allocation.
■ Statistics
Subgroups were created for demographic characteristics,clinical, lab-
oratory (cerebrospinal fluid; CSF), and MRI findings at disease onset.
Patients were differentiated with respect to steroid treatment for the
first event, monofocal versus multifocal disease presentation. Patients
who had a CSF analysis were differentiated with respect to the ab-
sence or presence of positive findings (defined by the occurrence of
oligoclonal bands and/or increased intrathecal immunoglobulin G
production). Subgroup analyses were also performed in patients with
symptoms exclusively indicating optic neuritis or brainstem/cerebel-
lar syndrome or spinal cord syndrome, with or without additional
signs (i.e. patients with presenting syndromes similar to those en-
rolled in the Controlled High-risk subjects Avonex Multiple Sclerosis
Prevention Study (CHAMPS) on the effect of once-weekly intramus-
cular IFNB-1a treatment at a dose of 30 μg) [3, 10]. Based on findings
of the screening MRI scan, subgroups were created of patients with
< 3 or ≥ 3 Barkhof criteria, < 9 or ≥ 9 hyper-intense lesions on the T2-
weighted scan (T2-lesions) and with respect to the absence or pres-
ence of Gd-enhancing lesions on the T1-weighted scan (Gd-lesions).
Since another study on once-weekly subcutaneous IFNB-1a treat-
ment at a dose of 22 μg (the ETOMS trial) reported that MRI charac-
teristics at baseline are only indicative for risk of CDMS in patients
with symptoms indicating monofocal involvement of the CIS (re-
ferred to as unifocal in the respective manuscript), the impact of MRI
findings was also examined in the subpopulation of monofocal BEN-
EFIT patients [2].
To descriptively show the impact of each of the aforementioned
demographic, clinical and MRI characteristics on the ‘natural’ risk of
CDMS independent of the IFNB-1b treatment effect, the 2-year cu-
mulative probability for CDMS was calculated in the placebo-treated
group using the Kaplan-Meier product-limit method. Data for pa-
tients in whom CDMS did not develop were censored on the date that
the patient was last clinically evaluated in the study.
The treatment effect within each subgroup was assessed by unad-
justed Cox proportional hazards regressions, giving unadjusted haz-
ard ratios (HRs) with 95 % CIs for the development of CDMS over the
2-year study period. To provide an estimate of the clinical relevance
of these findings, HRs are additionally expressed as risk reductions
(risk reduction = [1 – HR]  100 %). All subgroup analyses were per-
formed on a post hoc basis and p-values were not adjusted for multi-
ple testing.
Results
A total of 468 patients commenced treatment in the
BENEFIT study and contributed to the subgroup analy-
ses (see Fig. 1 for patient disposition); 292 patients re-
ceived IFNB-1b and 176 received placebo. Of these, 437
patients (93.4 %) completed the study as planned (either
reached month 24 or had CDMS before month 24). Fur-
ther disposition data are presented in Kappos et al. [11].
Baseline characteristics (presented in this manuscript
for the variables used for the subgroup analyses) did not
differ significantly between treatment groups for any
demographic,clinical or MRI variable (Table 1).Approx-
imately half of the patients had either a monofocal or
multifocal disease presentation.
■ Overall risk of CDMS and treatment effect
As reported previously [11], the risk of CDMS over 2
years was 45 % in the placebo group and 28 % in the
IFNB-1b group, based on Kaplan-Meier estimates, re-
sulting in a treatment effect of 47 % according to unad-
justed Cox proportional hazards regression (unadjusted
HR: 0.53; 95 % CI: 0.39–0.73; p < 0.0001) and 50 % using
the covariates age, sex, steroid treatment for the first
event,mono- or multifocal presentation at disease onset,
number of Gd-lesions and T2-lesions on the screening
MRI (HR: 0.50; 95 % CI: 0.36–0.70).
Fig. 1 Patient disposition
Received IFNB-1b: n = 292 (100%)
Lost to follow-up: n = 21 (7.2%)
Discontinued IFNB-1b: n = 44 (15.1 %)
Analysed: n = 292 (100%) Analysed: n = 176 (100%)
Analysis
Follow-up
Patients receiving
treatment
Main reasons: 
Main reasons: withdrawal of consent n = 9
adverse events n = 8
other n = 4
withdrawal of consent n = 8
adverse events n = 24
other n = 12
Received placebo: n = 176 (100%)
Lost to follow-up: n = 10 (5.7%)
Discontinued placebo: n = 18 (10.2%)
Main reasons: 
Main reasons: withdrawal of consent n = 7
lost to follow-up n = 2
other n = 1
withdrawal of consent n = 6
adverse events n = 1
other n = 11
4■ Subgroup analyses
Demographics, steroid treatment, CSF findings,
presenting symptoms
As shown in Table 2, for the placebo-treated CIS patients,
the risk of CDMS was higher in younger patients (pa-
tients with age at onset of < 30 vs. ≥ 30 years: 60 %
vs. 33 %, respectively; 30 years was the median age of the
BENEFIT population), in patients who were treated with
steroids (vs. without steroid treatment: 48 % vs. 38 %, re-
spectively), and in patients who had positive CSF find-
ings (vs. negative CSF findings: 49 % vs. 36 %, respec-
tively). The risk of CDMS in female and male
placebo-treated patients was comparable (45 %
vs. 47 %). The risk of CDMS ranged from 42 % in
placebo-treated patients with optic neuritis to 51 % in
patients with a spinal cord syndrome (43 % in patients
with brainstem/cerebellar syndrome).
With respect to demographics, steroid treatment,
CSF findings and presenting symptoms, the IFNB-1b
treatment effect was significant for all subgroups
analysed, with the exception of the small group of CSF-
negative patients (n = 47 patients). The treatment effect
size was comparable (approximately 50 %) in subgroups
of different age and gender (Table 2). The treatment ef-
fect tended to be more pronounced in patients who did
Table 1 Baseline characteristics for the BENEFIT treatment groups
IFNB-1b Placebo
(n = 292) (n = 176)
Women (%) 71 70
Age at onset below 30 years (%) 46 50
Steroid treatment for the first event (%) 72 70
CSF sample taken at the first event (%) 68 66
Of these: CSF typical for MS (%)* 86 83
Presenting syndromes (%)**
Optic neuritis 23 28
Brainstem/cerebellar syndrome 16 16
Spinal cord syndrome 20 17
Mono- or multifocal clinical onset
Monofocal onset (%) 52 53
Multifocal onset (%) 48 47
Patients with ≥ 3 Barkhof criteria 65 64
Patients with ≥ 9 T2-lesions (%) 71 70
Patients with ≥ 1 Gd-lesion (%) 44 40
In monofocal patients (n = 246):
Patients with ≥ 9 T2-lesions (%) 71 63
Patients with ≥ 1 Gd-lesion (%) 44 40
Patients with ≥ 9 T2 and ≥ 1 Gd-lesion(s) (%) 35 31
* Either positive oligoclonal bands or raised immunoglobulin G index.
** Patients with syndromes exclusively indicating damage to either the optic
nerves, brainstem/cerebellum or spinal cord
CSF cerebrospinal fluid; IFNB-1b interferon beta-1b; Gd gadolinium; MS multiple
sclerosis
Table 2 Risk for CDMS and treatment effects in subgroups: Demographics, steroids, CSF findings, and presenting syndromes
n Risk for Risk Hazard ratio ±95% CI for treatment effect p-value
CDMS in reduction
placeboa by IFNB-1bb
Age
<30 years 242 60% 51% 0.009
≥30 years 226 33% 48% 0.001
Sex
Male 137 47% 52% 0.017
Female 331 45% 45% 0.002
Steroids
No steroids 136 38% 62% 0.006
Steroids 332 48% 41% 0.004
CSFc
CSF negative 47 36% 28% 0.522
CSF positive 267 49% 45% 0.004
Presenting syndromed
Optic neuritis 116 42% 58% 0.016
Brainstem/cerebellum syndrome 74 43% 68% 0.013
Spinal syndrome 89 51% 51% 0.048
2 1.5 1 0.5 0
Treatment with Treatment with
placebo better IFNB-1b better
a According to Kaplan-Meier estimates; b According to unadjusted proportional hazards regression; risk reduction expressed as (1 – hazard ratio) x 100; c CSF was tested in
314 patients; d More than one symptom at presentation could occur
5not receive steroid treatment for the first event (vs. with
steroid treatment: 62 % vs. 41 %, respectively). In pa-
tients in whom symptoms were restricted to 1 of the 3
areas brainstem/cerebellar, optic nerve and spinal cord,
the treatment effect was 51 %, 58 % and 68 %, respec-
tively.
Clinical disease dissemination as well as MRI disease
dissemination and/or activity
As shown in Table 3, the risk of CDMS in placebo-treated
patients with a monofocal vs. multifocal disease presen-
tation was 47 % vs. 44 %. The risk of CDMS was 47 %
vs. 42 % in patients with ≥ 3 Barkhof criteria vs.< 3 Bark-
hof criteria, 48 % vs. 39 % in patients with ≥ 9 T2-lesions
vs. < 9 T2-lesions, and 52 % vs. 41 % in patients with at
least one Gd-lesion vs. no Gd-lesions on the screening
MRI.
A significant IFNB-1b treatment effect was found ir-
respective of the presence of disease activity and dis-
semination at presentation (Table 3). The treatment ef-
fect tended to be more pronounced in patients without
findings indicating disease dissemination clinically or
on MRI (treatment effect in monofocal vs. multifocal
patients: 55 % vs. 37 %, respectively; patients with < 3
Barkhof criteria vs. ≥ 3 Barkhof criteria: 58 % vs. 41 %,
respectively; patients with < 9 T2-lesions vs. ≥ 9 T2-le-
sions: 60 % vs. 43 %, respectively), but these trends did
not reach statistical significance. Similarly, the treat-
ment effect appeared more pronounced in patients
without activity on MRI (treatment effect in patients
without Gd-lesions vs. ≥ 1 Gd-lesions: 57 % vs. 38 %, re-
spectively).
MRI measures of dissemination and disease activity in
the monofocal subpopulation
As shown in Table 4, the risk of CDMS in monofocal
placebo-treated patients with ≥ 9 T2-lesions was 55 %
and 31 % in patients with < 9 T2-lesions. The risk of
CDMS in patients with Gd-lesions at screening was 63 %,
and 36 % in patients without Gd-lesions. The risk of
CDMS was highest in monofocal patients with ≥ 9 T2-le-
sions and ≥ 1 Gd-lesion (75 %).
A significant treatment effect of IFNB-1b was seen in
monofocal patients with ≥ 9 T2-lesions (61 %), and in
those with or without Gd-lesions (58 % versus 56 %, re-
spectively). In monofocal patients with < 9 T2-lesions,
the treatment effect was less pronounced (41 %) and did
not reach statistical significance. The treatment effect
was most pronounced (65 %) in monofocal patients with
≥ 9 T2-lesions and ≥ 1 Gd-enhancing lesion.
Of note, neither the risk of CDMS nor the treatment
effect was increased in multifocal patients with ≥ 9 T2-
lesions and/or at least 1 Gd-lesion at screening (data not
shown).
Table 3 Risk for CDMS and treatment effects in subgroups: Clinical and MRI measures indicating dissemination/activity of disease (all patients)
n Risk for Risk Hazard ratio ±95% CI for treatment effect p-value
CDMS in reduction
placeboa by IFNB-1bb
Clinical presentation
Monofocal 246 47% 55% 0.001
Multifocal 222 44% 37% 0.044
Number of T2 lesions
2–8 T2 lesions 138 39% 60% 0.008
≥9 T2 lesions 330 48% 43% 0.002
Presence of Gd lesionsc
No Gd+ lesions 266 41% 57% <0.001
≥1 Gd+ lesions 198 52% 38% 0.032
Barkhof criteria fulfilled
(after mono/multi)
≤2 Barkhof criteria 167 42% 58% 0.0036
≥3 Barkhof criteria 301 47% 41% 0.0058
≥9 T2 and ≥1 Gd+ lesions 164 55% 40% 0.0323
2 1.5 1 0.5 0
Treatment with Treatment with
placebo better IFNB-1b better
a According to Kaplan-Meier estimates; b According to unadjusted proportional hazards regression; risk reduction expressed as (1 – hazard ratio) x 100; c Gadolinium ad-
ministration was not performed in four patients
6Discussion
Certain variables, such as demographic factors, CSF
findings, treatment of the first event with steroids, as
well as clinical and MRI findings, have all been sug-
gested to impact on the risk of conversion to CDMS in
addition to the magnitude of the IFNB-1b treatment ef-
fect. We evaluated the effects of these variables on the
BENEFIT study population and compared these with re-
sults observed in other treatment trials or natural his-
tory studies in CIS patients [1–5, 10, 12, 19, 20].
We found conversion to CDMS to occur more fre-
quently in younger patients, which is in line with the
CHAMPS study [5]. Accordingly, relapse frequency has
previously been recognised to be higher in younger
patients [8, 13]. Also, the observation that patients who
had positive CSF findings convert more frequently has
been reported previously [18, 19]. The finding that pa-
tients in whom the presenting episode was treated with
intravenous steroids had a higher conversion rate ap-
pears to be somewhat surprising in the light of previous
observations, mainly from the Optic Neuritis Treatment
Trial, which indicated that steroids might have some
protective effects [4]. However, in our study, steroid
treatment of the first event was not randomly allocated
but provided at the discretion of the investigator. Subse-
quent analysis confirmed that there was an association
between the severity of the first event and steroid use in
BENEFIT patients (data not shown), hence the rate of
conversion paralleled (to some degree) the severity of
onset, which is more intuitive.
The rate of CDMS in our patients with optic neuritis
was similar to that of patients with a brainstem/cerebel-
lar syndrome and only slightly lower than that of pa-
tients with a spinal cord syndrome.This finding is in line
with a recent study by Tintore et al. that showed that the
CDMS rate was relatively independent of the presenting
symptom if additional MRI lesions were present; the
presence of at least 2 additional MRI lesions was a nec-
essary inclusion criterion in our study [12]. Tintore et al.
also reported that the lower rate of CDMS in patients
with optic neuritis observed in some epidemiologic
studies may be explained by a somewhat higher per-
centage of optic neuritis patients who had no lesions on
their MRI [6, 12].
The effect of IFNB-1b treatment on prolonging the
time to CDMS was robust in the entire cohort as well as
all pre-defined subgroups. However, in 2 of the addi-
tional subgroups examined here, treatment effect did
not reach statistical significance: patients with negative
CSF findings and monofocal patients with fewer than 9
T2-lesions. This may be in part due to the low numbers
of patients in these groups (N = 47 and N = 78, respec-
tively). The magnitude of the treatment effect was
largely independent of gender and age. It was interesting
to note that there was a profound treatment effect in pa-
tients who did not receive steroid treatment, which indi-
cated that this cohort with a potentially milder clinical
presentation also responded favourably to IFNB-1b
treatment. As previously reported, we found that the ef-
ficacy of IFNB-1b was robust in both mono- and multi-
focal CIS patients regardless of whether patients had
subclinical disease dissemination (< 9 vs. ≥ 9 T2-lesions)
Table 4 Risk for CDMS and treatment effects in subgroups: MRI measures indicating subclinical disease dissemination/activity in monofocal patients
n Risk for Risk Hazard ratio ±95% CI for treatment effect p-value
CDMS in reduction
placeboa by IFNB-1bb
Analysis in monofocal patients 246
Number of T2 lesions
2–8 T2 lesions 78 31% 41% 0.264
≥9 T2 lesions 168 55% 61% <0.001
Presence of Gd lesionsc
No Gd+ lesins 141 36% 56% 0.019
≥1 Gd+ lesions 104 63% 58% 0.005
≥9 T2 lesions and ≥1 Gd+ lesions 82 75% 65% 0.004
Barkhof criteria fulfilled
≤2 Barkhof criteria 167 42% 58% 0.0036
≥3 Barkhof criteria 301 47% 41% 0.0058
2 1.5 1 0.5 0
Treatment with Treatment with
placebo better IFNB-1b better
a According to Kaplan-Meier estimates; b According to unadjusted proportional hazards regression; risk reduction expressed as (1 – hazard ratio) x 100; c Gadolinium ad-
ministration was not performed in one monofocal patient
7or MRI activity (no vs. ≥ 1 Gd-lesions) on the screening
MRI [11].
Significant and strong treatment effects were also ob-
served in subgroups of patients with symptoms exclu-
sively indicating optic neuritis, brainstem/cerebellar or
spinal cord syndromes. In these groups, treatment ef-
fects were numerically stronger in patients with brain-
stem/cerebellar syndromes, followed by optic neuritis
and spinal cord syndromes. These results are slightly
different from the respective subgroup analyses of data
from CHAMPS study, where stronger IFNB-1a effects
were observed in patients with spinal cord syndromes,
followed by brainstem/cerebellar syndromes and optic
neuritis [3].
The BENEFIT study went to considerable effort to
centrally characterise the clinical findings as mono- or
multifocal in order to standardise the clinical assess-
ment.
Based on this thorough clinical characterisation, the
risk of CDMS was not found to be increased in multifo-
cal CIS patients. The contribution of MRI parameters to
defining prognosis is essentially restricted to patients
without clinical signs of disease dissemination at the
time of the CIS. Similar findings were reported for the
mono- and multifocal subpopulations of the ETOMS
study, as defined on the basis of the local investigator’s
assessment of patients’ symptoms [2].
When analysing the impact of MRI on the IFNB-1b
treatment effect in BENEFIT patients with clinically
monofocal disease presentation, we observed that the
treatment effect appeared to be stronger in monofocal
patients with at least 9 T2-lesions or Gd enhancement on
the initial MRI. This is in line with the numerically
stronger IFNB-1a treatment effect in CIS patients with at
least 9 T2-lesions and/or Gd enhancement as reported
for the CHAMPS study [3,15].Therefore, such MRI find-
ings at the time of the CIS appear to indicate a pro-
nounced treatment effect if patients do not have clinical
signs of disease dissemination (as with the monofocal
BENEFIT patients) or if they present with optic neuritis,
brainstem/cerebellar or spinal cord syndromes (as with
those enrolled in CHAMPS). Strikingly, in our study,
MRI findings were not a determinant of treatment effi-
cacy in the total study population, in either monofocal
or multifocal patients.
Our analyses have some limitations that must be
taken into consideration. Most importantly, since all of
the subgroup analyses were done on a post hoc basis and
p-values were not adjusted for multiple testing, the pre-
sented results are exploratory and do not allow final
conclusions for therapeutic decisions. In addition, our
analyses were performed on data from a 2-year obser-
vation period only, wherein only 45 % of placebo pa-
tients reached CDMS; longer-term data with more con-
versions would help to clarify if the early subgroup
trends we observed are significant. Most patients are be-
ing followed as part of an ongoing study and part of the
planned analysis will be to examine these early trends
over time.
In summary, our subgroup analyses show that pa-
tients included in the BENEFIT study had a risk factor
pattern for conversion to CDMS that is essentially in line
with that observed in other studies. There was a robust
treatment effect across the study population regardless
of: anatomical presentation syndrome, MRI disease bur-
den or activity, clinical features of dissemination or ini-
tial treatment with steroids. In monofocal CIS patients
MRI measures of subclinical disease dissemination or
activity at the time of the CIS seem to be especially valu-
able indicators of a higher risk of CDMS and also a more
pronounced treatment effect.
■ Acknowledgment This study was sponsored by Bayer Schering
Pharma AG, Germany.
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